DOCSLIB.ORG

12Th Annual International Meeting of the Institute of Human Virology of the University of Maryland School of Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
12Th Annual International Meeting of the Institute of Human Virology of the University of Maryland School of Medicine The INSTITUTE of HUMAN VIROLOGY Program Information and Acknowledgements contents scheDule oF events speaKers scheDule abstracts inDeX Welcome 12th Annual International Meeting of the Institute of Human Virology of the University of Maryland School of Medicine By Robert C. Gallo, Founder and Director, Institute of Human Virology and Giovanni Latorre, President, University of Calabria Dear colleagues and friends, University of Calabria President Giovanni Latorre and I wel- Maryland School of Medicine. This collaboration planted come you to the 12th Annual Meeting of the Institute of the idea for changing the venue of this 12th Annual Human Virology (IHV). For the first time since the meeting Meeting. Our meeting has always been a venue for sci- began in the mid-1970s at the National Cancer Institute, it ence of AIDS and cancer; this year we bring the meeting to is taking place outside the Baltimore/Washington, DC area. Italy, in part, as a recognition of our many international col- The setting for this year’s meeting, Tropea, Italy, is one of leagues and collaborators. extraordinary beauty and ancient historical contributions. We would like to thank several organizations who have The region is among the oldest civilization in Europe and committed their support while we are still in the early stag- includes the location of Pythagorus, Herodotus, and other es of planning this event: the National Cancer Institute and greats of the ancient world, as well as the land of origin of National Institute of Allergy and Infectious Disease of the many famous Greek legends, some told by Homer. Today, National Institutes of Health, the Office of AIDS Research, Tropea attracts visitors to the Costa degli Dei (Coast of the Italian Society for Medical Virology (SIVIM), Medestea, Gods), one of the most beautiful regions in Italy and food Sanofi-Pasteur, and Sanyo, Inc.. We will be pleased to recog- afficionados seeking the famous local red onion that was nize other supporting partners as the list grows. hailed by the Roman Pliny the Elder for its gastronomic The Annual Meeting has a traditional emphasis on the and healing potential. Nearby are the ancient Aeolian biology of HIV/AIDS, including the perspectives of basic islands. Together with Calabria and Sicily, their cultures science, clinical science and new treatment and prevention dating back thousands of years before Christ, also with approaches. In 2010 we are expanding the emphasis on their many legends. vaccines to recognize the importance of this area and learn It is important that we acknowledge Professor Arnaldo how recent successes may guide new directions in HIV Caruso, of the University of Brescia but who originally hails vaccine research and development. International vaccine from Calabria, chair of the Italian Organizing Committee; experts will describe vaccine immunogens that are moving without his vision and support, this meeting in Calabria through human clinical trials, efforts to define immune cor- would not be possible. Dr. Caruso currently holds an relates of protection, possible applications for therapeutic Adjunct Professorship at IHV and the University of Continued on page 4 2010 International Meeting of the Institute of Human Virology OCTOBER 4-8, 2010 The INSTITUTE of HUMAN VIROLOGY Program Information and Acknowledgements contents ScheDule oF events speaKers scheDule abstracts inDeX Continued from page 3 vaccination and a range of vaccine delivery strategies that of Terra Mariana from the country of Estonia in 2006, for are bringing us closer, everyday, to effective protection work by him on behalf of Estonia in the late 1980’s and from HIV disease. Recognizing the important parallels of early 1990’s when Estonia regained its independence from HIV and cancer, we include discussions of cancer-causing the Soviet Union in 1991 in a bloodless transition. Huge viruses, new cancer vaccines and fundamental research worked on behalf of Estonia with the U.S. Administration in cancer. In developed countries, cancer is emerging as and Congress during this period as well as in Estonia. the leading cause of death for persons with HIV, and these Harry and his wife, Reba, founded and operate two founda- fields are inexorably linked in terms of both science and tions which award college scholarships to Nebraska high medicine. We also emphasize the problems of HIV/AIDS school seniors. Over the past five years, they have awarded in the developing world by inviting experts on the specific 30 scholarships to students who attend colleges and impacts of HIV/AIDS on sub-Saharan Africa. universities in Nebraska, Iowa, Kansas and South Dakota. This year, in keeping with the meeting’s focus on vaccines, Prior honorees include: John Evans, Robert Gray, Martin we are honored to present the IHV Lifetime Achievement Delaney, and Stewart Greenebaum. Award for Scientific Contributions to Dr. Rino Rappuoli of For the first time, we are presenting an award for teach- Novartis Vaccines in Sienna, Italy. Rappuoli, currently the ing excellence. This award, from our Institute and his Global Head of Vaccines Research for Novartis Vaccines & many students and colleagues, is a “surprise” for Michele Diagnostics (Siena, Italy), was elected as a foreign associate La Placa, MD. He has been educating medical students of the National Academy of Sciences in 2005. He spent his and researchers in the field of microbiology in Italy since career developing vaccines for pertussis, meningitis, and 1954. Dr. La Placa is the author of the manual “Principles Helicobacter pylori and is jointly responsible for engineer- of Medical Microbiology,” (Esculapio, Bologna, Italy), the ing the carrier protein used in many conjugate vaccines. most widely used textbook of Microbiology in the medical He is credited with launching the field of reverse vaccin- schools of Italian universities, which is currently in its 12th ology, the first fruits of which are revealed in the special edition. Inaugural Article of the Proceedings of the US National We hope everyone will take the opportunity to visit the Academy of Sciences, where he describes a universal vac- town square in Cosenza, the provincial capitol of the cine for serogroup B meningococcus. Previous recipients Tropea area of Calabria, where large modern sculptures of the IHV Lifetime Achievement Award for Scientific by world famous artists are exhibited and a fountain and Contributions are: Isaac Witz, Maxine Singer, Manfred the central square honors the Kennedy family. We expect Eigen, Paul Zamecnik, Jan Svoboda, Alexander Rich, Hilary that Ms. Kathleen Kennedy Townsend, former lieutenant Koprowski, Maurice Hilleman, and George Klein. governor of Maryland and daughter of U.S. Senator Robert We will also be presenting the IHV Lifetime Achievement F. Kennedy, who is the Chair of our Board of Advisors will Award for Public Service to Harry Huge, Esq. Harry is a attend. friend of the Institute and was with us at the beginning We are grateful to those joining us in Tropea this year and when the State of Maryland recruited Bob Redfield, Bill are confident that this meeting will write another impor- Blattner, and Robert Gallo. He is a practicing attorney in tant chapter in the book of human retrovirology. I also Charleston, South Carolina and has enjoyed a long and want to acknowledge my co-workers David Pauza and Beth distinguished law career, serving as an arbitrator on the Peterson, whose tireless efforts for this meeting now reach National Tobacco Arbitration Panel, a Special Master for the fruition. U.S. District Court for the District of Columbia; and chair- man of the United Mine Workers Health and Retirement Fund. He is currently co-counsel representing family Cordially, members of the victims of the September 11, 2001 attacks victims and in late 2002, he was appointed co-prosecutor with the Chief German Federal Prosecutor by the German Federal Criminal Court in the trials of Hamburg cell ter- rorists. Harry was also awarded the Order of the Cross Robert Gallo Giovanni Latorre Director and Professor President Institute of Human Virology University of Calabria 2010 International Meeting of the Institute of Human Virology OCTOBER 4-8, 2010 The INSTITUTE of HUMAN VIROLOGY Program Information and Acknowledgements contents scheDule oF events speaKers scheDule abstracts inDeX The Institute of Human Virology www.ihv.org Mission Statement The Institute of Human Virology (IHV) is a world-class center of excellence focusing on chronic viral diseases and virally linked cancers. IHV is dedicated to biomedical research leading to improved treatment and prevention of these diseases. Our unique structure connects cohesive, multidisciplinary research and clinical programs so that new treatments are streamlined from discovery to patients. IHV is forging local and inter- national programs for research and treatment of human disease. Robert C. Gallo Director Co-Director, Division of Basic Science and Vaccine Research William A. Blattner Associate Director Director, Division of Epidemiology and Prevention Robert R. Redfield Associate Director Director, Division of Clinical Care and Research C. David Pauza Associate Director George Lewis Co-Director, Division of Basic Science and Vaccine Research Joseph L. Bryant Director, Division of Animal Models Dave Wilkins Chief Operating Officer 2010 International Meeting of the Institute of Human Virology OCTOBER 4-8, 2010 The INSTITUTE of HUMAN VIROLOGY Program Information and Acknowledgements contents ScheDule oF events speaKers scheDule abstracts inDeX Tropea, Calabria, Italy We are pleased to announce the IHV Meeting, for the first time in its history, will be held outside the Baltimore/Washington, DC area. The location for the meeting is Tropea, Italy. Tropea, specifically, and its region, Calabria, are a well-kept secret by American standards, and those who join us are in for a special treat. Located on the western tip of the Italian peninsula on the Tyrrhenian Sea, the coastline is affectionate- ly known as the “Costa degli Dei,” or the “Coast of the Gods.” Tropea is a very popular vacation destina- tion among Italians and other Europeans.
Load more

Recommended publications
  • T. Franklin Williams Scholars Program
    Developing a New Generation of Medical Subspecialists with Expertise in Aging and Care of the Elderly T. Franklin Williams Scholars Program Report to T. Franklin Williams Scholars Program Evaluation Team ASP Geriatrics Steering Committee Integrating Geriatrics Project Evaluation Team May 2011 Submitted by: Erika D. Tarver Project Administrator Association of Specialty Professors 330 John Carlyle Road Suite 610 Alexandria, VA 22314 T: (703) 341-4540 F: (703) 519-1890 [email protected] Kevin P. High, MD Principal Investigator William R. Hazzard, MD Co-Principal Investigator Table of Contents Narrative Progress Report Application and Award Progress Summary of Success of T. Williams Scholars Program Appendices A. 2008 Scholars 24-Month Progress Reports Neena S. Abraham, MD (Note: This is Dr. Abraham’s final report) Steven G. Coca, DO Jeffrey G. Horowitz, MD Danelle F. James, MD Heidi Klepin, MD George C. Wang, MD 2009 Williams Scholars Progress Reports and Summary of 18-Month Questionnaire B. Peter Abadir, MD 12-month Progress Report C. Kathleen M. Akgun, MD 12-Month Progress Report Publication D. Alison Huang, MD 12-Month Progress Report Publication E. Eswar Krishnan, MD 12-Month Progress Report Publication F. Rohit Loomba, MD Publication G. Sharmilee Nyenhuis, MD 12-Month Progress Report Publication H. Peter P. Reese, MD 12-Month Progress Report Publication I. Erik B. Schelbert, MD 12-Month Progress Report Publication J. Helen Keipp Talbot, MD 12-Month Progress Report Publication K. Summary of 18-Month Questionnaire 2010 Williams Scholars Mentor Interviews and Summary of Six-Month Questionnaire L. Kellie Hunter-Campbell, MD Six-Month Mentor Interview M.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. Jaworski PII: S2319-4170(20)30209-2 DOI: https://doi.org/10.1016/j.bj.2020.11.011 Reference: BJ 374 To appear in: Biomedical Journal Received Date: 2 September 2020 Revised Date: 6 November 2020 Accepted Date: 22 November 2020 Please cite this article as: Jaworski JP, Neutralizing monoclonal antibodies for COVID-19 treatment and prevention, Biomedical Journal, https://doi.org/10.1016/j.bj.2020.11.011. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Chang Gung University. Publishing services by Elsevier B.V. TITLE: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. JAWORSKI Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina KEYWORDS: SARS-CoV-2, Coronavirus, Monoclonal Antibody, mAb, Prophylaxis, Treatment CORRESPONDING AUTHOR: Dr. Juan Pablo Jaworski, DVM, MSc, PhD. Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria Las Cabañas y de los Reseros (S/N), Hurlingham (1686), Buenos Aires, Argentina Tel / Fax: 054-11-4621-1447 (int:3400) [email protected] ABSTRACT The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
    [Show full text]
  • INFO PACK Transnational Training
    Erasmus+ - KA2 Strategic Partnership Project title – EPOC: Entrepreneurship: a Product of Our Culture Reference number: 2018-1-IT02-KA204-048462 INFO PACK Transnational training Vibo Valentia Italy, 07 - 13 June 2019 1 Table of Contents Organisational information .............................................................................................. 3 1. Host organization ........................................................................................................... 3 2. Traveling to Italy ............................................................................................................. 4 3. Information about accommodation and training ................... Error! Bookmark not defined. 4. Useful information ......................................................................................................... 5 Information about the programme ................................................................................... 8 1. The training programme ................................................................................................. 8 2. Proposed preparational material .................................................................................. 11 3. Administration related to the training ........................................................................... 12 Information about the place of the training .................................................................... 13 1. Calabria .......................................................................................................................
    [Show full text]
  • HIV?AIDS Researchers at the NIH Clinical Center
    The NIH Clinical Center treats a diverse group of patients from all over the world. It also draws researchers from different cultures and backgrounds. Learn more about some of the many researchers who conduct their work on the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the Clinical Center. Thomas C. Quinn, M.D., M.Sc., conducts research for the National Institute of Allergy and Infectious Diseases at the NIH Clinical Center. He is a senior investigator and chief of the International HIV/STD Section of the Laboratory of Immunoregulation. Dr. Quinn obtained his M.D. from Northwestern University. He was a research associate in infectious diseases in the NIAID Laboratory of Parasitic Diseases and completed a fellowship in infectious diseases at the University of Washington. Since 1981, he has been assigned to the division of infectious diseases at Johns Hopkins University, where he became a professor of medicine in 1991. Dr. Quinn is a member of the Institute of Medicine and the National Academy of Sciences and is a fellow of the American Association for the Advancement of Science. His major areas of research are: Definition of epidemiologic features of HIV-1 and HIV-2 infections in developing countries and the United States Assessment of biomedical interventions to control HIV, including circumcision, prevention of mother-to-child transmission, pre-exposure prophylaxis, and vaccine development Assessment of the frequency of Chlamydia trachomatis infections in selected populations using noninvasive sensitive nucleic-acid amplification assays for diagnosis Evaluations of interventions to control blinding trachoma due to Chlamydia trachomatis in sub-Saharan Africa See the full program description.
    [Show full text]
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The
    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
    [Show full text]
  • Portobello Village | Hotel & Resort
    Portobello Village | Hotel & Resort 2 Portobello Village Portobello Village 3 PORTOBELLO VILLAGE | THE NEWEST AND MOST EXCLUSIVE RESORT ON THE COAST Portobello Village is a unique opportunity to invest in one of the fastest-growing areas in Southern Italy. Create your own piece of paradise, in a com- munity of entrepreneurs, investors, creatives and other global life-stylists. Portobello Village, Hotel & Resort lies in a fan- tastic location, overlooking one of the most beautiful & certainly historical cities, Tropea, which is surrounded by some of the best white sandy beaches on the Costa Degli Dei. The site which is a lush green hillside spread- ing out over more than 80000 sqm, with as many property options & typologies to attract the international traveller & investor. The views are sensational. The sunrises are magical. And the white sandy beaches, well, we will let you experience those for yourselves…. 4 Portobello Village Concept Portobello Village is more than an investment; this is a lifestyle opportunity for anyone wanting to escape, for shorter or extended periods, while still being very connected with the world. Every piece of land is ready to build, and we More than half of the total area will have private offer exclusive villas, townhouses & suites recreation areas reserved exclusively for Porto- in the luxury 5 Star Hotel, all sustainably de- bello residents and their guests. We also have signed. Construction of the first phase has access to a private beach through our own Por- already begun starting in the middle quarter tobello Beach club. This will be serviced by a of 2018 with the initial works to prepare the bus shuttle running ever hour through-out the full site for ease of marketing and sales i.e.
    [Show full text]
  • Nci-Plan-2013.Pdf
    THE NATIONAL CANCER PROGRAM MANAGING THE NATION’S RESEARCH PORTFOLIO AN ANNUAL PLAN AND BUDGET PROPOSAL FOR FISCAL YEAR 2013 National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Contents 1 Foreword 4 Provocative Questions 8 Center for Cancer Genomics 16 Introduction to Cancer Profiles 18 Pancreatic Ductal Adenocarcinoma 22 Colorectal Cancer 26 B-Cell Lymphoma 30 Renal Cell (Kidney) Cancer 34 GI Stromal Cancer 39 Research Focus: Comorbidities 42 Research Focus: Circulating Tumor Cells 44 Research Focus: Reducing Cancer Health Disparities 50 The Frederick National Laboratory for Cancer Research 61 Small Business Innovation Research, Small BusinessTechnology Transfer (SBIR, STTR) 66 NCI Center for Global Health 72 NCI-Designated Cancer Centers 83 Glossary of Terms 84 Budget FOREWORD The National Cancer Program MANAGING THE NATION’S RESEARCH PORTFOLIO his year marks the 75th anniversary of the founding of the National Cancer Institute, the first so-called “categorical institute” of what has become the National Institutes of Health, with its 27 Institutes and Centers. Over the years, the Congress and the public have generously supported the TNCI—and the NIH generally—with sustained budgetary increases. This was especially true for the NCI during the rapid expansion of its budget following the National Cancer Act of 1971 and for the NIH, including the NCI, during the 5-year doubling of its budget, launched in 1998. Both of these eras of rapid growth were remarkably fruitful. The first launched the pursuit of cancer genes and the molecular basis of oncogenesis, laying the foundation for the transformation of clinical oncology that is now occurring.
    [Show full text]
  • NIHAA Update 1Velco111es Lerters and Eastern Europe and at the Undergradu­ 1968, a Period of Considerable Growth News from Its Readers
    The Newsletter of the L NIH Alumni Association Summer 1999 Vol. 11, No. 2 date NIHAA Members Enjoy June Annual Meeting with Henney, Morella Alumni attendi ng the 1999 annual meeting of the NIH.AA were given a first-band briefing on FDA by Dr. Jane E. Henney, the receml y appointed FDA commissioner. Tbe audience also participated in a question and answer exchange witb Rep. Constance A. Morella (R-Md.), who was presented with tbe NIHAA 1999 Public Service Award. Almost I00 alumni attended the June 12 morning meeting at the Mary Woodard Lasker Center on the NIH campus. Henney, wbo was NCI deputy director for five of her lO years at NIH (1985-1995) spoke infonnalJy on some of FDA's principal concerns at this time: the agency's efforts to speed Shown at the NIHAA annual meeting are (from I} NIH alumna Dr. Jane E. Henney, FDA up review without sacrifice of quality commissioner, who spoke on "Back Home Again via Indiana, Kansas and New Mexico," and safeguards; tbe need for recruiting Dr. John F. Sherman, Rep. Constance A. Morella (R-Md.), who received the 1999 NIHAA Public Service Award, and Dr. William S. Jordan, Jr., outgoing NIHAA president. (see A flflual Meeting, p. 12) Director's Advisors Bat 6 for 7 in June Meeting In This Issue Page Choppin To Give Third Research Festival '99 J By Rich McManus NIHAA Shannon Lecture Ca/e11dar 5 The scorecard at the end of a daylong Dr. Purnell W. Cboppin, president of .News .from a11d about Nlf/A;/ me111be1:r (f session of lhe advisory committee to the Howard Hughes Medical lnstirure, the NIH director (ACD) on June 3 read A le11erjro1111he 11e111 Nlf/AIJ preside111 IO will deliver the third James A.
    [Show full text]
  • Study Protocol, Including Amendment
    Document Type: Study Protocol, including Amendment (Informed Consent Template located in Appendix I of the Protocol Version 1.0 and Version 2.0) Official Title: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults NCT Number: NCT03478891 Document/Date: Protocol Amendment Version 2.0: April 6, 2018 Protocol Version 1.0: February 21, 2018 Version 2.0 April 6, 2018 VACCINE RESEARCH CENTER Protocol VRC 608 (NIH 18-I-0069) A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF A HUMAN MONOCLONAL ANTIBODY, VRC-EBOMAB092-00-AB (MAB114), ADMINISTERED INTRAVENOUSLY TO HEALTHY ADULTS Study Product Provided by: Vaccine Research Center (VRC) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Bethesda, MD Clinical Trial Sponsored by: NIAID/VRC/NIH, Bethesda, Maryland IND 138,090 Sponsored by: VRC/NIAID/NIH, Bethesda, Maryland Principal Investigator: Martin Gaudinski, MD VRC/NIAID/NIH Bethesda, MD 20892 IRB Initial Review Date: January 8, 2018 PRODUCT: VRC-EBOMAB092-00-AB (MAb114) PROTOCOL: VRC 608, VERSION 2.0 PROTOCOL DATE: APRIL 6, 2018 TABLE OF CONTENTS Page ABBREVIATIONS....................................................................................................................... 5 PRÉCIS.......................................................................................................................................... 8 1. INTRODUCTION............................................................................................................
    [Show full text]
  • See the Vaccine Research Center Brochure
    Vaccine Research Center NIAID National Institute of Allergy and Infectious Diseases U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Letter from John R. Mascola, M.D., NIAID Vaccine Research Center Director, and Anthony S. Fauci, M.D., NIAID Director The Dale and Betty Bumpers Vaccine Research Center (VRC) was created by Presidential Executive Order in 1997 to accelerate the development of a vaccine directed against the devastating global pandemic caused by HIV. The VRC began its vital HIV work in 2000 and has since further expanded its scope and capabilities to combat other high-burden diseases such as influenza, respiratory syncytial virus (RSV), malaria, and tuberculosis, as well as biodefense threats and emerging infectious diseases, including Ebola, chikungunya, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), West Nile, and Zika. As an intramural research arm of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), the VRC is led by an integrated team of specialists in various disciplines, including immunology, virology, structural biology, and bioengineering. By encompassing these scientific disciplines under one roof, together with the capability to conduct human clinical trials, the VRC accelerates the process of scientific discovery leading to the design and development of prototype vaccines and biologics to protect against infectious diseases. The VRC operates as the closest analog at NIH to a private
    [Show full text]
  • Il Viaggio Di Lidia Bastianich in Calabria Itinerari Enogastronomici
    The journey of Lidia Bastianich to Calabria Wine and food itineraries Il viaggio di Lidia Bastianich in Calabria Itinerari enogastronomici summary|Sommario introduction|introduzione 2 recipes|ricette Welcome to Calabria Benvenuti in Calabria Bomba Calabrese Bloody Mary 9 Bomba Calabrese Bloody Mary itinerary 1|itinerario 1 4 Buccunotti 10 Riviera dei Cedri Buccunotti Riviera dei Cedri Pasta of the Poor (Dromsat) 17 Pasta dei Poveri (Dromsat) itinerary 2|itinerario 2 12 Fettuccine with dried cod fish and white bread 18 Arbëreshë culture and norman splendor Fettuccine con baccalà e mollica di pane Sibari Carnaroli Risotto with Guanciale, Cultura Arbëreshë e splendore normanno Caciocavallo Silano and Licorice Powder 26 itinerary 3|itinerario 3 20 Risotto Carnaroli di Sibari con guanciale, The Coast of the Achaean caciocavallo silano e polvere di liquirizia La Costa degli Achei Raschiatelli with artichokes and lemon from Rocca Imperiale 27 itinerary 4|itinerario 4 30 Raschiatelli carciofi e limone Magna Grecia and Sila di Rocca Imperiale Magna Grecia e Sila Lagane and chickpeas 36 Lagane e ceci itinerary 5|itinerario 5 40 Mpacchiuse potatoes 37 The Coast of the Gods Patate Mpacchiuse Bread and Tomato Salad with Tropea Onions 46 La Costa degli Dei Insalata di Pomodori e Pane con Cipolle di Tropea itinerary 6|itinerario 6 50 Fileja and ‘Nduja 47 Violet Coast and Jasmine Riviera Fileja e ‘Nduja Bergamot and ricotta parfait 54 Costa Viola e Riviera dei Gelsomini Parfait di ricotta con Bergamotto itinerary 7|itinerario 7 58 Swordfish Bagnara Style
    [Show full text]
  • Vaccine Research Center, NIAID, NIH
    4/17/2018 PIPELINE OF HIV MONOCLONAL ANTIBODIES FOR PREVENTION OF HIV Session on Antibody‐Mediated Prevention 2018 Global Vaccine and Immunization Research Forum (GVIRF) 20‐22 March 2018 Bangkok, Thailand Barney S. Graham, MD, PhD Deputy Director Vaccine Research Center, NIAID, NIH Dale and Betty Bumpers Vaccine Research Center Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health 2017 VRC Principal Investigators and Program Directors 1 4/17/2018 VRC Research & Development: From AIDS to Zika August 2000 AIDS/HIV Chikungunya Ebola/Marburg Influenza Malaria MERS-CoV, SARS RSV Smallpox Tuberculosis W/E/V equine encephalitis viruses West Nile virus, Zika Engineering Lab Pilot Plant Vaccine Evaluation Clinic Immunology Lab Partners for Advanced Development Functional Activity of Anti-Viral Antibodies • Neutralization – Aggregation – Attachment blocking – Cleavage inhibition – Fusion inhibition – Preventing particle release • Fc‐mediated functions – Antibody dependent cell‐mediated cytotoxicity (NK, Macrophage, Neutrophil) – Complement binding and activation • Opsinization and clearance by non‐susceptible cells • Blocking pathogenic immunomodulatory molecules 2 4/17/2018 Long History of Using Antibodies to Treat Infectious Diseases (Serum Therapy) Shibasaburo Kitasato 1890: Emil von Behring and Shibasaburo Kitasato worked on “anti‐ toxins” for tetanus and diphtheria that led to concept for serum therapy 1901: Emil von Behring ‐ 1901 Nobel Prize in Physiology or Medicine “For his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of Wernicke, Frosch, and medical science and thereby placed in the hands of the physician a Behring in Koch’s Berlin Lab victorious weapon against illness and deaths".
    [Show full text]